MOTS-c
Mitochondrial open reading frame of the 12S rRNA-c — 16 amino acids
A small peptide encoded within mitochondrial DNA that regulates metabolic homeostasis in animals. Human trial data on administering the peptide essentially does not exist.
- Category
- Fat Loss & Metabolic
- Half-life
- Not established in humans
- Cycle length
- Not established — no human protocol exists
- Level
- advanced
Overview
MOTS-c is one of a small group of peptides encoded inside mitochondrial DNA rather than the nuclear genome — a discovery that changed how mitochondria are viewed, from pure power plants to signalling organelles. It is sixteen amino acids long and appears to act as a metabolic messenger, moving between the mitochondrion, the cytoplasm and the nucleus. In animals it improves glucose handling and, in some studies, produces adaptations that overlap with exercise. That is why it has become popular in biohacking circles. It is also why the page you are reading is blunt: the interesting findings are in mice, and there is essentially no published evidence for what the peptide does when people inject it.
How it works
MOTS-c is encoded within the mitochondrial 12S ribosomal RNA region. It appears to act partly by translocating to the nucleus and influencing the folate–methionine cycle and the antioxidant response, and partly by activating AMPK signalling. In muscle this increases glucose uptake and fatty-acid oxidation. Circulating MOTS-c levels change with fasting, exercise and age, which is what frames it as a stress- and exercise-responsive signalling peptide rather than a conventional drug.
Reported benefits
- Improved insulin sensitivity and glucose handling in rodent studies
- Reduced fat mass and improved exercise capacity in some animal models
- Activates AMPK, a central energy-sensing pathway
- Human observational studies link circulating levels to metabolic health and training status
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
There is no established human dose. Preclinical studies have used roughly 0.5 mg/kg per day in mice, usually by injection. No trial of administering MOTS-c to humans has been published.
Any figure quoted for human use is an extrapolation from rodent studies, and the assumption that mouse and human pharmacology scale on body weight is unreliable for peptides with receptor-mediated effects.
Community-reported: 5–10 mg two to three times weekly, in four- to eight-week courses. There is no human dose-finding study, so no reported figure has an evidence basis.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
The literature is preclinical and mechanistic. Rodent studies report that exogenous MOTS-c improves insulin sensitivity, reduces fat accumulation and increases physical performance, largely through AMPK-dependent pathways. Human work so far is observational: circulating MOTS-c correlates with metabolic and training status and declines with some age-related metabolic decline. That combination — solid mechanism, plausible biology, no human intervention data — is the pattern that attracts both genuine researchers and grey-market sellers. For a reader deciding anything practical, the honest assessment is that MOTS-c is an interesting mitochondrial signalling molecule and a completely untested human intervention.
Preclinical & non-clinical data
Rodent and cell studies show improved insulin sensitivity, reduced fat mass, higher exercise capacity and AMPK activation. Circulating human levels change with fasting and training, but no trial has given the peptide to people.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Interest has grown quickly since 2022 and the reporting is still thin. Users describe improved energy, better tolerance for training volume and, less often, nothing at all — with most detailed accounts admitting the effect could be placebo given the price. The most telling gap: almost nobody in the public accounts tracks the endpoint the compound is studied for, which is metabolic. There is no insulin-sensitivity bloodwork in these threads at all.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- No human adverse-event data exists for injected MOTS-c
- Injection-site reactions and sterility risks inherent to reconstituted powders
- Unknown effects of long-term AMPK activation in humans
Safety notes
There is no human safety data. Because the observed effects run through AMPK and cellular energy sensing, chronic activation is a theoretical concern rather than a documented one. Exercise itself triggers much of the same signalling, and the practical alternative to injecting a mitochondrial peptide is training, which is where the actual human evidence lives. Do not use alongside glucose-lowering medication without clinical oversight.
Stacking
Sometimes discussed alongside other metabolic peptides such as semaglutide or AOD-9604. Nothing has been studied in combination, so any such protocol is an experiment with no monitoring attached.
Related compounds
Retatrutide
LY3437943 — triple GLP-1 / GIP / glucagon receptor agonist
Fat Loss & Metabolic
The triple agonist that produced the largest weight reductions yet reported in a randomised obesity trial.
Cagrilintide
Long-acting amylin analogue — studied in combination with semaglutide
Fat Loss & Metabolic
An amylin analogue built to sit alongside a GLP-1 and push appetite suppression further.
AOD-9604
hGH fragment 176–191
Fat Loss & Metabolic
A fragment of growth hormone sold for fat loss, with trial results far more modest than the marketing.